Page last updated: 2024-10-25

ciglitazone and Transfusion Reaction

ciglitazone has been researched along with Transfusion Reaction in 1 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Transfusion Reaction: Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.

Research Excerpts

ExcerptRelevanceReference
" Treatment with ciglitazone, which inhibits platelet CD40L expression, had no effect on pulmonary and systemic inflammation compared to controls."3.77Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. ( Boon, L; Gerards, MC; Jongsma, G; Juffermans, NP; Tuinman, PR; Vlaar, AP, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tuinman, PR1
Gerards, MC1
Jongsma, G1
Vlaar, AP1
Boon, L1
Juffermans, NP1

Other Studies

1 other study available for ciglitazone and Transfusion Reaction

ArticleYear
Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury.
    Clinical and experimental immunology, 2011, Volume: 165, Issue:2

    Topics: Acute Lung Injury; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Blood Platelets; Bronch

2011